BIAF · bioAffinity Technologies, Inc. · Analyst Estimates
$6.08
+0.03 (+0.41%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current expected level of operating expenditures, current expected levels of revenue, and the cash and cash equivalents on hand at June 30, 2026, of $2.4 million, management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements contained in this Quarterly Report.”View the 10-Q filed Aug 7, 2026
Market Cap
$3.72M
Shares
540,115
Volume · Oct 5
106.52K
Avg daily vol (29 sessions)
6.44M
Analyst Estimates
Compare analyst forecasts for bioAffinity Technologies, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 12:58 UTC · Publication dates shown per estimate · 4 metric / period groups
FY ending 2025-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
Q ending 2026-03-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|